Sequence information
DRAVP ID DRAVPc027
Name Cilgavimab(AZD1061)
Sequence Not available
Molecular Formula C6626H10218N1750O2078S44
Condition/Disease COVID-19
Group Approved
Type Antibody
Description Cilgavimab is an extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Cilgavimab is not approved for any indication by the FDA. Cilgavimab, in combination with tixagevimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,5 and was approved in Canada soon after, on April 14, 2022.
Active sequence/Structure
Comment
No comments found No comments found No comments found No comments found
External Links
DrugBank Accession Number DB16393
Pubchem ID 440964522
CHEMBL ID Not Available
UNII 1KUR4BN70F
CAS 2420563-99-9
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO) | Coronavirus Disease 2019 (COVID‑19) Treatment | Active, not recruiting | Phase 3 | University of Minnesota |
| NCT05321394 | Non-inferiority Trial on Treatments in Early COVID-19 | Coronavirus Disease 2019 (COVID‑19) Treatment | Recruiting | Phase 3 | Azienda Ospedaliera Universitaria Integrata Verona |
| NCT04723394 | Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE) | Coronavirus Disease 2019 (COVID‑19) Treatment | Active, not recruiting | Phase 3 | AstraZeneca |
